Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs abrdn Physical Palladium Shares ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.86 (market cap $8.04B), while abrdn Physical Palladium Shares ETF trades at $23.89. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| BIO | PALL | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $339.75 | $37.18 |
52-Week Low | $241.71 | $19.96 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.73, down 1.47% with bearish technical signals from moving averages. The ETF faces headwinds from palladium's 47% price decline from January 2026 highs, though recent news highlights potential buying opportunities as the metal approaches technical support levels. A 1:5 stock split occurred on May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook remains cautious due to weak palladium pricing and industrial demand concerns, though some analysts see value at current levels. Key risks include commodity price volatility and Federal Reserve policy impacts. Investment appeal hinges on palladium's supply-demand dynamics improving from current depressed conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
